Engineered mice point to new target for pain relief

December 23, 1999

DURHAM, N.C.--Duke University Medical Center scientists have discovered a biological mechanism in mice that prolongs morphine's painkilling effects. Their findings could lead to the development of new drugs that make morphine last longer and relieve pain at lower doses.

The researchers report in the Dec. 24 Science that morphine prevents pain longer and more completely when administered to mice engineered to lack a protein switch called "beta-arrestin 2." Beta-arrestin normally comes into play after morphine is administered by blocking the chemical signal that morphine sends to the brain to suppress pain sensation. Thus, when the researchers genetically altered mice to lack beta-arrestin, morphine remained effective for longer periods in those mice, and lower morphine doses were required to achieve pain relief in these mice.

The findings come from the laboratories of Dr. Robert Lefkowitz and Marc Caron, both Howard Hughes Medical Institute investigators at Duke Medical Center.

At the heart of the study is a metabolic process known as "desensitization," in which an initially receptive cell develops a reduced response to a chemical stimulus. For example, desensitization occurs when a person who has entered a coffee shop quickly becomes accustomed to the aroma and no longer notices it. The stimulus hasn't disappeared, but the olfactory sensory cells that first responded to the smells ignore the stimulus after a time.

Beta-arrestin is part of the cell's machinery that produces desensitization to morphine after the morphine molecule initially binds to a receptor on the surface of nerve cells. Receptors are proteins that relay chemical signals from outside the cell to the cell's machinery to cause a cellular response.

"When the morphine receptor is activated by binding morphine, it transmits a message that initially suppresses pain perception," explained Laura Bohn, a postdoctoral fellow in Caron's laboratory who performed the experiments with the mice. "It also triggers beta-arrestin to turn off the receptor so it isn't constantly being activated. Without beta-arrestin, morphine's action is enhanced and lasts longer."

The scientists discovered that when morphine was given to mice that had the gene for beta-arrestin knocked out, the mice were resistant to a standard, mildly uncomfortable exposure to a warmed surface almost three times longer than were normal mice.

Because beta-arrestin is important for turning off the response to a variety of signals that a cell receives, the researchers were not surprised that the mice would show a change in their response to morphine. They were surprised, however, to discover the extent of the role that beta-arrestin plays to cause morphine's effects to subside.

"We were amazed that beta-arrestin was, in fact, very important in determining how quickly the analgesic properties of morphine wear off," recalled Caron.

If the findings in mice apply to humans, new drugs might be developed to block the action of beta-arrestin, said Caron. Such drugs might be used in combination with lower doses of morphine to extend the amount of pain relief it can provide and reduce the side effects, he said.

Morphine is currently the "gold standard" of analgesic drugs and is used to treat moderate to severe pain following surgery and chronic pain experienced, for example, by cancer patients. However, morphine sometimes produces nausea, and may suppress breathing if given in too great a dose. Also, chronic administration of morphine produces tolerance, such that patients need greater and greater doses to achieve pain relief.

The scientists also emphasized the possibility that blocking beta-arrestin might not only enhance morphine's action, but may also prevent the process of tolerance and even addiction.

"We don't yet know how tolerance and physical dependence will relate to desensitization," said Lefkowitz. "But there is a chance that maybe the beta-arrestin-deficient mice won't become tolerant or physically dependent. That's why it's exciting to think about the potential uses of these mice."

Other contributors to the study include Raul Gainetdinov, a research assistant professor of cell biology in Caron's laboratory; Karsten Peppel, a research assistant professor of medicine at Duke; and Fang-Tsyr Lin, a postdoctoral fellow in Lefkowitz's laboratory who created the mutant mice by genetic engineering.

Duke University Medical Center

Related Morphine Articles from Brightsurf:

Virtual reality illuminates the power of opioid-associated memories
The brain acts differently when remembering environments associated with drug use.

Intranasal sufentanil as good as IV morphine for emergency pain relief, study finds
In patients presenting to an emergency department with severe traumatic pain, intranasal sufentanil was as good as standard-of-care intravenous morphine for pain relief, according to a new study published this week in PLOS Medicine by Marc Blancher of Grenoble Alpes University Hospital, France, and colleagues.

New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.

New painkiller lasts longer, is less addictive than morphine
As an alternative to morphine, researchers present a new nano-painkiller they've tested in rodents.

How the poppy evolved its pain-relieving properties
The unveiling of the poppy genome reveals how a collection of genes fused to endow the plant with its pain-relieving compounds; the plant underwent a notable genome duplication event about 7.8 million years ago, the study's authors say.

A wakefulness molecule is abundant in the brains of heroin addicts
Researchers have discovered that the brains of heroin addicts harbor a greater number of neurons that produce hypocretin, a molecule involved in arousal and wakefulness, and one lacking in abundance in people with narcolepsy.

Change in brain cells linked to opiate addiction, narcolepsy
Two discoveries -- one in the brains of people with heroin addiction and the other in the brains of sleepy mice -- shed light on chemical messengers in the brain that regulate sleep and addiction.

Potential new treatment for drug addiction relapse revealed
Research published in Addiction Biology by scientists at the University of Bath reveals a new potential mechanism for combatting drug addiction relapse.

Body's 'natural opioids' affect brain cells much differently than morphine
A new study led by UC San Francisco scientists shows that brain cells, or neurons, react differently to opioid substances created inside the body -- the endorphins responsible for the 'natural high' that can be produced by exercise, for example -- than they do to morphine and heroin, or to purely synthetic opioid drugs, such as fentanyl.

Study suggests failed osteoarthritis drug could help treat opioid addiction
A study from Indiana University suggests that a drug proven safe for use in people may prevent opioid tolerance and physical dependence when used with opioid-based pain medications.

Read More: Morphine News and Morphine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to